Eiger BioPharmaceuticals (EIGR) News Today → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free EIGR Stock Alerts Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineStockNews.com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)americanbankingnews.com - May 2 at 5:24 AMFirm Retention Summary: Eiger BioPharmaceuticalswsj.com - May 1 at 10:40 AMRequiem for Eiger Biopharmaceuticalswsj.com - April 8 at 7:20 PMPeninsula biotech files for Chapter 11 bankruptcy protectionbizjournals.com - April 2 at 3:05 AMEiger BioPharmaceuticals Files for Bankruptcywsj.com - April 1 at 10:04 PMHealthcare stocks fade as obesity-drug optimism fadesmarketwatch.com - April 1 at 10:04 PMMetabolic Diseases-Focused Eiger BioPharmaceuticals Files For Bankruptcy, Stock Nosedivesmsn.com - April 1 at 5:03 PMEiger Biopharmaceuticals Files for Chapter 11 Bankruptcyfinance.yahoo.com - April 1 at 5:03 PMmarketbeat.com - April 1 at 12:26 PMmarketbeat.com - April 1 at 12:03 PMmarketbeat.com - April 1 at 12:03 PMEiger reportedly files for Chapter 11, stock plunges 52%msn.com - April 1 at 12:03 PMmarketbeat.com - April 1 at 11:57 AMmarketbeat.com - April 1 at 11:31 AMmarketbeat.com - April 1 at 11:17 AMEiger BioPharmaceuticals Files for Voluntary Chapter 11 Protectionglobenewswire.com - April 1 at 11:12 AMmarketbeat.com - April 1 at 10:33 AMmarketbeat.com - April 1 at 10:24 AMmarketbeat.com - April 1 at 10:24 AMmarketbeat.com - April 1 at 10:12 AMEIGR Eiger BioPharmaceuticals, Inc.seekingalpha.com - March 20 at 12:27 PMmarketbeat.com - March 4 at 9:40 AMNew Natomas industrial property owner Eiger Capital could be buying more local assetsbizjournals.com - February 8 at 9:06 PMPanattoni sells part of Natomas Advanced Logistics Center to Eiger Capitalbizjournals.com - February 4 at 1:14 AMEiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japanfinance.yahoo.com - January 18 at 7:12 PMmarketbeat.com - January 8 at 6:02 AMEiger BioPharmaceuticals announces 1-for-30 reverse stock splitmsn.com - January 4 at 1:45 PMEiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Splitfinance.yahoo.com - January 4 at 8:44 AM‘Bob Eiger’ Trends on X After Elon Musk Blasts the Disney CEO With Multi-Tweet Typoyahoo.com - December 7 at 7:16 PMEiger BioPharmaceuticals Insiders US$2.1m Short Of Breakeven On Stock Purchasefinance.yahoo.com - December 4 at 9:11 AMEiger BioPharmaceuticals, Inc.: Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - November 11 at 8:10 AMAnalysts Are Bullish on These Healthcare Stocks: Ocular Therapeutix (OCUL), Eiger Biopharmaceuticals (EIGR)markets.businessinsider.com - September 15 at 7:32 AMEiger BioPharmaceuticals Shares Hit New Lows After Scrapped Hepatitis D Studymarketwatch.com - September 13 at 6:38 PMEiger To Discontinue Peginterferon Lambda Trial In CHD Patients; Stock Down In Premarketmarkets.businessinsider.com - September 13 at 6:38 PMWhy Is Hepatitis Player Eiger BioPharma Stock Trading Lower Today?msn.com - September 13 at 6:38 PMWhy Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?investorplace.com - September 13 at 10:02 AMEiger to discontinue late-stage hepatitis drug study over safety concernsreuters.com - September 13 at 2:38 AMEiger to discontinue hepatitis drug study over safety concernsnews.yahoo.com - September 12 at 9:37 PMEiger BioPharmaceuticals to Discontinue Chronic Hepatitis Delta Study, Ends Licensing Talksmarketwatch.com - September 12 at 9:37 PMEiger to stop late stage trial in hepatitis D patients, stock slumps ~36% after hoursseekingalpha.com - September 12 at 9:37 PMUPDATE 1-Eiger to discontinue hepatitis drug study over safety concernsfinance.yahoo.com - September 12 at 9:37 PMEiger to discontinue hepatitis drug studyreuters.com - September 12 at 4:28 PMmarketbeat.com - September 12 at 4:04 PMCiti Sticks to Their Buy Rating for Eiger Biopharmaceuticals (EIGR)markets.businessinsider.com - August 30 at 6:47 AMEiger BioPharmaceuticals, Inc.: Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - August 15 at 5:52 PMAnalysts Offer Insights on Healthcare Companies: Eiger Biopharmaceuticals (EIGR) and Atossa Therapeutics (ATOS)markets.businessinsider.com - August 15 at 5:52 PMEiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updatemarkets.businessinsider.com - August 14 at 8:55 PMFreewell Eiger matte box aims to transform your filmmakingyahoo.com - August 3 at 1:36 PMEiger BioPharmaceuticals (EIGR) Price Target Decreased by 59.60% to 3.40msn.com - July 6 at 8:48 PMBaird Maintains Eiger BioPharmaceuticals (EIGR) Outperform Recommendationmsn.com - July 1 at 1:18 PM Get Eiger BioPharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter. Email Address The biggest energy story ever? (Ad)Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie… For the full story, click here. EIGR Media Mentions By Week EIGR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EIGR News Sentiment▼0.000.33▲Average Medical News Sentiment EIGR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EIGR Articles This Week▼11▲EIGR Articles Average Week Get Eiger BioPharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Windtree Therapeutics News Today 9 Meters Biopharma News Today Enveric Biosciences News Today Mustang Bio News Today Innovative Eyewear News Today CohBar News Today Dynatronics News Today Quoin Pharmaceuticals News Today Onconetix News Today Altamira Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EIGR) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eiger BioPharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
